• Warning signs in the market     Monday, 24 Mar 2014 | 12:00 PM ET

    The FMHR traders discuss what warning signs bull investors should be looking for in the stock market and concerns about a biotech bubble.

  • What's working in biotech: CELG, ALXN & more     Monday, 24 Mar 2014 | 8:05 AM ET

    U.S. lawmakers sent a letter to Gilead requesting information on pricing for its hepatitis c drug Sovaldi. Christopher Raymond of R.W. Baird.

  • Analyst likes large cap biotechs     Friday, 21 Mar 2014 | 2:06 PM ET

    Discussing the market's big reaction to news U.S. lawmakers requested information about Gilead's hepatitis C drug Sovaldi, and which stocks are attractive in the sector, with Geoff Porges, Bernstein Research senior analyst.

  • Biotech weighs on S&P     Friday, 21 Mar 2014 | 1:02 PM ET

    CNBC's Dominic Chu reports the health care sector is being dragged down by the biotech sector. Congressional Democrats asked biotech company Gilead to provide insight on pricing for its hepatitis C drug Sovaldi.

  • US Democrats ask Gilead about pricing     Friday, 21 Mar 2014 | 12:30 PM ET

    CNBC's Sheila Dharmarajan reports on the decline in the Nasdaq because of the hit to the biotechs. Gilead received a letter from senior Democrats requesting a briefing on the pricing for its hepatitis C drug Sovaldi.

  • MediWound makes US market debut     Thursday, 20 Mar 2014 | 10:48 AM ET

    MediWound develops treatments for severe burns and hard to heal wounds. Gal Cohen, MediWound CEO, discusses his company's medical solutions and the results of its IPO.

  • Pisani: Momentum names holding up     Friday, 14 Mar 2014 | 3:42 PM ET

    CNBC's Bob Pisani discusses the IPO of Castlight Health and how classic momentum stocks are trading, and CNBC's Sheila Dharmajan looks at what biotech stocks are getting hit hard.

  • Biotech bubble formation?     Friday, 14 Mar 2014 | 12:46 PM ET

    CNBC's Bertha Coombs discusses potential froth in the biotech sector due to an uptick in biotechnology IPOs.

  • XBI is 'best way to biotech': Trader     Wednesday, 12 Mar 2014 | 12:45 PM ET

    FMHR traders Mike Murphy and Pete Najarian debate the play on the S&P biotech ETF.

  • Biotech firm Dendreon is set to begin selling its prostate cancer vaccine "Provenge" in Europe. John Johnson, Dendreon chairman & CEO, discusses the European launch and addresses investor concerns.

  • Buy Regeneron today: Pro     Wednesday, 5 Mar 2014 | 2:40 PM ET

    Sam Isaly of OrbiMed Advisors, explains why he likes the new products of Regeneron, and why he expects Intermune to go higher.

  • Hot health care trades     Tuesday, 25 Feb 2014 | 12:15 PM ET

    CNBC's Bertha Coombs reports on which sectors and stocks are impacted by Obamacare, and the FMHR traders share their top health care stock picks.

  • Best biotech stock plays     Thursday, 20 Feb 2014 | 2:40 PM ET

    Barbara Ryan, FTI Consulting managing director, analyzes the biotech sector and reveals which companies are on the forefront of therapies worth investing in.

  • Pharma for man's best friend     Monday, 10 Feb 2014 | 3:17 PM ET

    Steven St. Peter, Aratana Therapeutics president & CEO, discusses the need for pet medical pharmaceuticals and the market for pet insurance.

  • Biotech boom keeps going     Wednesday, 29 Jan 2014 | 1:45 PM ET

    CNBC's Sheila Dharmarajan reports on what factors contribute to the biotech sector outperforming this year.

  • LONDON, Jan 29- In experiments that could open a new era in stem cell biology, scientists have found a simple way to reprogramme mature animal cells back into an embryonic-like state that allows them to generate many types of tissue.

  • LONDON, Jan 29- In experiments that could open a new era in stem cell biology, scientists have found a cheap and easy way to reprogramme mature cells from mice back into an embryonic-like state that allowed them to generate many types of tissue.

  • As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.

  • Biotech: 2014's favored child     Thursday, 16 Jan 2014 | 12:15 PM ET

    Mark Schoenebaum, ISI Group analyst, breaks down the red hot biotech sector and explains why Gilead Sciences is his best play.

  • Twitter almost impossible to value: Analyst     Tuesday, 14 Jan 2014 | 10:50 AM ET

    Dan Fitzpatrick, StockmarketMentor.com president & technical analyst, takes a look at the charts to get a technical read on Twitter. Also a look at why Fitzpatrick likes the biotech sector.

Most Popular Video

Thursday, 17 Apr 2014 | 4:13 PM ET

Dissecting today's market activity and the current state of financials, with Yra Harris, Praxis Trading partner; Larry Glazer, Mayflower Advisors; CNBC contributor Carol Roth; "Fast Money" Guy Adami and CNBC's Kate Kelly.

Thursday, 17 Apr 2014 | 5:46 PM ET

CNBC voice over talent Jim Birdsall shares the top 5 sayings from traders on "Fast Money" over the years.

Thursday, 17 Apr 2014 | 6:40 PM ET

Mad Money's Jim Cramer reflects on CNBC's evolution over the past 25 years.